Biomoda, Inc., Maker of Early Lung Cancer Detection Test, Begins Trading on OTC-BB Under Symbol 'BMOD'.

ALBUQUERQUE, N.M. -- Biomoda, Inc. of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today that its common stock has begun trading on the OTC Bulletin Board under the ticker symbol "BMOD".

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells that are extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is amenable to use by automated sample reading equipment platforms. This will allow large populations to be screened for cancer at a reasonable cost with high specificity and greater sensitivity and accuracy than most other types of cancer screening.

For additional information, visit the Biomoda web site at www.biomoda.com.

Lung cancer claims more lives than any other cancer. An estimated 162,460 deaths from lung cancer will occur in the United States during 2006. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

"Safe Harbor" Statement: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.